Nostrum Laboratories Revenue and Competitors
Estimated Revenue & Valuation
- Nostrum Laboratories's estimated annual revenue is currently $24.3M per year.
- Nostrum Laboratories's estimated revenue per employee is $238,441
Employee Data
- Nostrum Laboratories has 102 Employees.
- Nostrum Laboratories grew their employee count by 2% last year.
Nostrum Laboratories's People
Name | Title | Email/Phone |
---|---|---|
1 | VP | Reveal Email/Phone |
2 | Assistant Warehouse Manager | Reveal Email/Phone |
Nostrum Laboratories Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 221 | 16% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 91 | -10% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 16 | -6% | $114.3M | N/A |
#8 | $7.2M | 28 | -7% | N/A | N/A |
#9 | $13.7M | 51 | -9% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Nostrum Laboratories?
www.nostrumlabs.com
keywords:N/AN/A
Total Funding
102
Number of Employees
$24.3M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nostrum Laboratories News
2022-04-17 - Global Dermatitis Herpetiformis Drugs Market 2022 Industry ...
... Acros Organics; 3B Scientific; Allergan; Valeant Canada LP; GlaxoSmithKline Pharmaceuticals Ltd. Nostrum Laboratories, Inc.
2022-04-06 - Acetazolamide Market Size estimated to exhibit at a 4.8 ...
... Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Heritage Pharmaceuticals Inc., Nostrum Laboratories Inc., Novast Laboratories...
2022-03-22 - Pfizer yanks blood pressure meds amidst ongoing, industry ...
To start the year, Viona Pharmaceuticals recalled 33 lots of metformin hydrochloride ... A year earlier, Nostrum Laboratories twice voluntarily recalled its...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $14.8M | 102 | 5% | N/A |
#2 | $15.8M | 102 | 40% | N/A |
#3 | N/A | 102 | 7% | N/A |
#4 | $7.5M | 102 | 4% | N/A |
#5 | $25.5M | 102 | 6% | N/A |